An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 11-12, 2006, Pages 960-963

  Cone, Lawrence A ^a   Stone, Richard A ^a   Schlievert, Patrick M ^b   Sneider, Ronald A ^a   Rubin, Andrew M ^a   Jesser, Kenneth ^a   Renker, Stacey W ^a  

^a EISENHOWER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTISTREPTOLYSIN; AZITHROMYCIN; BACTERIUM ANTIBODY; CEFTRIAXONE; CELECOXIB; DOPAMINE; DROTRECOGIN; HLA DR ANTIGEN; IMMUNOGLOBULIN; MOXIFLOXACIN; PROCOAGULANT;

ADULT; ARTICLE; BLADDER DISEASE; CASE REPORT; COUGHING; DIALYSIS CATHETER; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; HAND EDEMA; HEMODIALYSIS; HUMAN; HYPOTENSION; IMMUNE RESPONSE; KIDNEY FAILURE; LABORATORY TEST; MULTIPLE ORGAN FAILURE; MYALGIA; NONHUMAN; RESPIRATORY FAILURE; SKIN EXFOLIATION; SORE THROAT; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TOXIC SHOCK SYNDROME;

ANTI-INFECTIVE AGENTS; COMBINED MODALITY THERAPY; DIALYSIS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PROTEIN C; RECOMBINANT PROTEINS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 33845285901     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500373224     Document Type: Article

References (25)

1. Cone, LA and Woodard, DR and Schlievert, PM and Tomory, GS. (1987) Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes N Engl J Med, 317, pp. 146-9.
2. Stevens, DL and Tanner, MH and Winship, J and Swarts, R and Rice, KM and Schlievert, PM and Kaplan, EL. (1989) N Engl J Med, 321, pp. 1-7.
3. Bartter, T and Dascal, A and Carrol, K and Curley, FJ. (1988) 'Toxic strep syndrome'. A manifestation of group A streptococcal infection Arch Intern Med, 148, pp. 1421-4.
4. Demers, B and Simor, AE and Vellend, H and Schlievert, PM and Byrne, S and Jamieson, F and (1993) Severe invasive group A streptococcal infections in Ontario, Canada 1987-1991 Clin Infect Dis, 16, pp. 792-800.
5. The Working Group on Severe Streptococcal Infections. Defining the group A toxic shock syndrome: Rationale and consensus definition. JAMA 1993;269:390-1.
6. Davies, HD and McGeer, A and Schwartz, B and Green, K and Cann, D and Sim, A and (1996) Invasive group A streptococcal infections in Canada N Engl J Med, 335, pp. 547-54.
7. Cavaillon, J-M and Mueller-Alouf, H and Alouf, JE. (1997) Cytokines in streptococcal infections Adv Exp Med Biol, 418, pp. 929-31.
8. Fast, DJ and Schlievert, PM and Nelson, RD. (1989) Toxic shock syndrome-associated staphylococcal and streptococcal pyogenic toxins are potent inducers of tumor necrosis factor production Infect Immun, 57, pp. 291-4.
9. Mueller-Alouf, H and Alouf, D and Gerlach, D and Ozegowski, JH and Fitting, C and Cavaillon, J-M. (1994) Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci and lipopolysaccharide Infect Immun, 62, pp. 4915-21.
10. Norrby-Tegland, A and Thulin, P and Bing, S and Gran, BS and Kolb, M and McGeer, A and (2001) Evidence for superantigen involvement in severe group A streptococcal infection J Infect Dis, 184, pp. 853-60.
11. Proft, T and Louise Moffatt, S and Berkahn, CJ and Fraser, JD. (1999) Identification and characterization of novel superantigens from Streptococcus pyogenes J Exp Med, 189, pp. 89-102.
12. Esmon, CT and Taylor, FB, Jr and Snow, TR. (1991) Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C Thromb Haemost, 66, pp. 160-5.
13. Taylor, FB, Jr and Stearns-Kurosawa, DJ and Kurosawa, S and Ferrell, G and Chang, ACK and Laszik, Z and (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis Blood, 95, pp. 1680-6.
14. Bernard, GR and Vincent, J-L and Laterre, P-F and La Rosa, SP and Dhaipau, JF and Lopez-Rodriguez, A and (2001) Efficacy and saftey of recombinant human activated protein C for severe sepsis N Engl J Med, 344, pp. 699-709.
15. Joyce, DE and Gelbert, L and Ciaccia, A and DeHoff, B and Grinnell, BW. (2001) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis J Biol Chem, 276, pp. 11199-203.
16. Zeigler, EJ and Fischer, CJ, Jr and Sprung, CL and (1991) Treatment of Gram-negative bacteremia and septic shock with HA1A human monoclonal antibody against endotoxin N Engl J Med, 324, pp. 29-36.
17. Abraham, E and Anzueto, A and Gutierrez, G and Tessler, S and San Pedro, G and Wundirink, R and (1998) Double-blind, randomized, controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock Lancet, 351, pp. 929-33.
18. Fisher, CJ, Jr and Agosti, JM and Opal, SM and Lowry, SF and Balk, RA and Sadoff, JC and (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein N Engl J Med, 334, pp. 1697-1702.
19. Opal, SM and Fisher, CJ, Jr and Dhainaut, JF and Vincent, JL and Brase, R and Lowry, SF and (1997) The confirmatory interleukin-1 receptor antagonist trial in sepsis: A phase III randomized, double-blind, placebo-controlled, multicenter trial Crit Care Med, 25, pp. 1115-24.
20. Warren, BL and Eid, A and Singer, P and Pillay, SS and Carl, P and Novak, I and (2001) High dose antithrombin III in severe sepsis: A randomized controlled trial JAMA, 286, pp. 1869-78.
21. Abraham, E and Reinhart, K and Opal, S and (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial JAMA, 290, pp. 238-47.
22. Kaul R, McGeer A, Norby-Teglund A, Korb M, Schwartz B, O'Rourke K, The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: A comparative observational study. Clin Infect Dis 1999;28:800-7.
23. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P,, The Streptig Study Group. Intravenous immunolobilin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
24. Kotb, M and Norrby-Teglund, A and McGeer, A and El Sherbini, H and Dorak, MT and Kurshid, K and (2002) An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections Nature Med, 8, pp. 1398-1404.
25. Martin, JM and Green, M and Barbadora, KA and Wald, ER. (2002) Erythromycin-resistant group A sreptococci in schoolchildren in Pittsburgh N Engl J Med, 346, pp. 1200-6.